table of content
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Vasomotor Symptoms of Menopause Treatment Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
1.2.2 Estetrol
1.2.3 Fezolinetant
1.2.4 FP-101
1.2.5 HBN-2
1.2.6 Others
1.3 Market by Application
1.3.1 Global Vasomotor Symptoms of Menopause Treatment Market Share by Application: 2017 VS 2021 VS 2028
1.3.2 Hospital
1.3.3 Homecare
1.3.4 Clinic
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Vasomotor Symptoms of Menopause Treatment Market Perspective (2017-2028)
2.2 Vasomotor Symptoms of Menopause Treatment Growth Trends by Region
2.2.1 Vasomotor Symptoms of Menopause Treatment Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Vasomotor Symptoms of Menopause Treatment Historic Market Size by Region (2017-2022)
2.2.3 Vasomotor Symptoms of Menopause Treatment Forecasted Market Size by Region (2023-2028)
2.3 Vasomotor Symptoms of Menopause Treatment Market Dynamics
2.3.1 Vasomotor Symptoms of Menopause Treatment Industry Trends
2.3.2 Vasomotor Symptoms of Menopause Treatment Market Drivers
2.3.3 Vasomotor Symptoms of Menopause Treatment Market Challenges
2.3.4 Vasomotor Symptoms of Menopause Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Vasomotor Symptoms of Menopause Treatment Players by Revenue
3.1.1 Global Top Vasomotor Symptoms of Menopause Treatment Players by Revenue (2017-2022)
3.1.2 Global Vasomotor Symptoms of Menopause Treatment Revenue Market Share by Players (2017-2022)
3.2 Global Vasomotor Symptoms of Menopause Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Vasomotor Symptoms of Menopause Treatment Revenue
3.4 Global Vasomotor Symptoms of Menopause Treatment Market Concentration Ratio
3.4.1 Global Vasomotor Symptoms of Menopause Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Vasomotor Symptoms of Menopause Treatment Revenue in 2021
3.5 Vasomotor Symptoms of Menopause Treatment Key Players Head office and Area Served
3.6 Key Players Vasomotor Symptoms of Menopause Treatment Product Solution and Service
3.7 Date of Enter into Vasomotor Symptoms of Menopause Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Vasomotor Symptoms of Menopause Treatment Breakdown Data by Type
4.1 Global Vasomotor Symptoms of Menopause Treatment Historic Market Size by Type (2017-2022)
4.2 Global Vasomotor Symptoms of Menopause Treatment Forecasted Market Size by Type (2023-2028)
5 Vasomotor Symptoms of Menopause Treatment Breakdown Data by Application
5.1 Global Vasomotor Symptoms of Menopause Treatment Historic Market Size by Application (2017-2022)
5.2 Global Vasomotor Symptoms of Menopause Treatment Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Vasomotor Symptoms of Menopause Treatment Market Size (2017-2028)
6.2 North America Vasomotor Symptoms of Menopause Treatment Market Size by Country (2017-2022)
6.3 North America Vasomotor Symptoms of Menopause Treatment Market Size by Country (2023-2028)
6.4 United States
6.5 Canada
7 Europe
7.1 Europe Vasomotor Symptoms of Menopause Treatment Market Size (2017-2028)
7.2 Europe Vasomotor Symptoms of Menopause Treatment Market Size by Country (2017-2022)
7.3 Europe Vasomotor Symptoms of Menopause Treatment Market Size by Country (2023-2028)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Vasomotor Symptoms of Menopause Treatment Market Size (2017-2028)
8.2 Asia-Pacific Vasomotor Symptoms of Menopause Treatment Market Size by Country (2017-2022)
8.3 Asia-Pacific Vasomotor Symptoms of Menopause Treatment Market Size by Country (2023-2028)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
9 Latin America
9.1 Latin America Vasomotor Symptoms of Menopause Treatment Market Size (2017-2028)
9.2 Latin America Vasomotor Symptoms of Menopause Treatment Market Size by Country (2017-2022)
9.3 Latin America Vasomotor Symptoms of Menopause Treatment Market Size by Country (2023-2028)
9.4 Mexico
9.5 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Vasomotor Symptoms of Menopause Treatment Market Size (2017-2028)
10.2 Middle East & Africa Vasomotor Symptoms of Menopause Treatment Market Size by Country (2017-2022)
10.3 Middle East & Africa Vasomotor Symptoms of Menopause Treatment Market Size by Country (2023-2028)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
11 Key Players Profiles
11.1 Amgen Inc.
11.1.1 Amgen Inc. Company Detail
11.1.2 Amgen Inc. Business Overview
11.1.3 Amgen Inc. Vasomotor Symptoms of Menopause Treatment Introduction
11.1.4 Amgen Inc. Revenue in Vasomotor Symptoms of Menopause Treatment Business (2017-2022)
11.1.5 Amgen Inc. Recent Development
11.2 EndoCeutics, Inc.
11.2.1 EndoCeutics, Inc. Company Detail
11.2.2 EndoCeutics, Inc. Business Overview
11.2.3 EndoCeutics, Inc. Vasomotor Symptoms of Menopause Treatment Introduction
11.2.4 EndoCeutics, Inc. Revenue in Vasomotor Symptoms of Menopause Treatment Business (2017-2022)
11.2.5 EndoCeutics, Inc. Recent Development
11.3 Euroscreen S.A.
11.3.1 Euroscreen S.A. Company Detail
11.3.2 Euroscreen S.A. Business Overview
11.3.3 Euroscreen S.A. Vasomotor Symptoms of Menopause Treatment Introduction
11.3.4 Euroscreen S.A. Revenue in Vasomotor Symptoms of Menopause Treatment Business (2017-2022)
11.3.5 Euroscreen S.A. Recent Development
11.4 MenoGeniX, Inc.
11.4.1 MenoGeniX, Inc. Company Detail
11.4.2 MenoGeniX, Inc. Business Overview
11.4.3 MenoGeniX, Inc. Vasomotor Symptoms of Menopause Treatment Introduction
11.4.4 MenoGeniX, Inc. Revenue in Vasomotor Symptoms of Menopause Treatment Business (2017-2022)
11.4.5 MenoGeniX, Inc. Recent Development
11.5 Mithra Pharmaceuticals S.A.
11.5.1 Mithra Pharmaceuticals S.A. Company Detail
11.5.2 Mithra Pharmaceuticals S.A. Business Overview
11.5.3 Mithra Pharmaceuticals S.A. Vasomotor Symptoms of Menopause Treatment Introduction
11.5.4 Mithra Pharmaceuticals S.A. Revenue in Vasomotor Symptoms of Menopause Treatment Business (2017-2022)
11.5.5 Mithra Pharmaceuticals S.A. Recent Development
11.6 Pherin Pharmaceuticals, Inc.
11.6.1 Pherin Pharmaceuticals, Inc. Company Detail
11.6.2 Pherin Pharmaceuticals, Inc. Business Overview
11.6.3 Pherin Pharmaceuticals, Inc. Vasomotor Symptoms of Menopause Treatment Introduction
11.6.4 Pherin Pharmaceuticals, Inc. Revenue in Vasomotor Symptoms of Menopause Treatment Business (2017-2022)
11.6.5 Pherin Pharmaceuticals, Inc. Recent Development
11.7 Pivot Pharmaceuticals Inc
11.7.1 Pivot Pharmaceuticals Inc Company Detail
11.7.2 Pivot Pharmaceuticals Inc Business Overview
11.7.3 Pivot Pharmaceuticals Inc Vasomotor Symptoms of Menopause Treatment Introduction
11.7.4 Pivot Pharmaceuticals Inc Revenue in Vasomotor Symptoms of Menopause Treatment Business (2017-2022)
11.7.5 Pivot Pharmaceuticals Inc Recent Development
11.8 Radius Health, Inc.
11.8.1 Radius Health, Inc. Company Detail
11.8.2 Radius Health, Inc. Business Overview
11.8.3 Radius Health, Inc. Vasomotor Symptoms of Menopause Treatment Introduction
11.8.4 Radius Health, Inc. Revenue in Vasomotor Symptoms of Menopause Treatment Business (2017-2022)
11.8.5 Radius Health, Inc. Recent Development
11.9 TherapeuticsMD, Inc.
11.9.1 TherapeuticsMD, Inc. Company Detail
11.9.2 TherapeuticsMD, Inc. Business Overview
11.9.3 TherapeuticsMD, Inc. Vasomotor Symptoms of Menopause Treatment Introduction
11.9.4 TherapeuticsMD, Inc. Revenue in Vasomotor Symptoms of Menopause Treatment Business (2017-2022)
11.9.5 TherapeuticsMD, Inc. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
